Geneoscopy develops a screening methodology to noninvasively diagnose colorectal cancer using biomarkers in stool samples.
Geneoscopy has raised $105.0M in total funding. The most recent round was Series C. The last funding was announced in January 2025.
Geneoscopy's investors include LabCorp, Cultivation Capital, Bio-Rad Laboratories, Dorm Room Fund, Petrichor Healthcare Capital Management.
Geneoscopy is headquartered in Saint Louis, United States.
Geneoscopy develops a screening methodology to noninvasively diagnose colorectal cancer using biomarkers in stool samples.
Geneoscopy is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Geneoscopy — Funding & Investors." VCBacked, January 8, 2025, https://www.vcbacked.co/company/geneoscopy. Accessed July 19, 2026.
VCBacked. (2025). Geneoscopy — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/geneoscopy
{{cite web |title=Geneoscopy — Funding & Investors |url=https://www.vcbacked.co/company/geneoscopy |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated